The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome Mice
Open accessAbstract
Fragile X syndrome (FXS) is the leading inherited cause of autism and intellectual disability. Aberrant synaptic translation has been implicated in the etiology of FXS, but most lines of research on therapeutic strategies have targeted protein synthesis indirectly, far upstream of the translation machinery. We sought to perturb p70 ribosomal S6 kinase 1 (S6K1), a key translation initiation and elongation regulator, in FXS model mice. We found that genetic reduction of S6K1 prevented elevated phosphorylation of translational control molecules, exaggerated protein synthesis, enhanced mGluR-dependent long-term depression (LTD), weight gain, and macro-orchidism in FXS model mice. In addition, S6K1 deletion prevented immature dendritic spine morphology and multiple behavioral phenotypes, including social interaction deficits, impaired novel object recognition, and behavioral inflexibility. Our results support the model that dysregulated protein synthesis is the key causal factor in FXS and that restoration of normal translation can stabilize peripheral and neurological function in FXS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many of the other classic behavioural phenotypes used as outcome measures in preclinical studies are inconsistently observed in Fmr1-KO mice (such as open field, rotarod, elevated plus-maze, marble burying, self-grooming and most social paradigms).”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [49]
In the citing paper
“As a result, the rescue of these behavioural phenotypes has been difficult to consolidate and to use as a guide for clinical studies30,49,56,64,65.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [49]
In the citing paper
“One striking conclusion of the broad array of preclinical studies is that these core deficits can be consistently rescued by more than ten genetic approaches and multiple classes of pharmacological compounds including mGluR antagonists (MPEP, fenobam, mavoglurant and CTEP), GABA agonists, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), mechanistic target of rapamycin (mTOR) inhib”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
SUnSET, a nonradioactive method to monitor protein synthesis
Schmidt, E. K., Clavarino, G., Ceppi, M., & Pierre, P. (2009) · Nature Methods · doi:10.1038/nmeth.1314 · Cited by 1,706
Self-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Self-citationRibosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Flagged first, then by citations
Cited by
Sorted by citations
Lipton, J. O., & Şahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 771
Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders
Lee, E., Lee, J., & Kim, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.011 · Cited by 468
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491
Self-citationMolecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz, A., Zmorzyńska, J., & Jaworski, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 405
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
Translational control in synaptic plasticity and cognitive dysfunction
Buffington, S. A., Huang, W., & Costa-Mattioli, M. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014100 · Cited by 348
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Wang, X., Bey, A. L., Katz, B. M., Badea, A., Kim, N., David, L. K., Duffney, L. J., Kumar, S., Mague, S. D., Hulbert, S. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms11459 · Cited by 330
Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders
Sahin, M., & Sur, M. (2015) · Science · doi:10.1126/science.aab3897 · Cited by 295
Dysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275
Self-citationSignalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L., Long, S., Ke, X., Fukunaga, K., Lu, Y., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 295
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al‐Houqani, M., Sadeq, A. S., Ojha, S. K., Sasse, A., & Sadek, B. S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 276
Grayson, B., Léger, M., Piercy, C., Adamson, L., Harte, M., & Neill, J. C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.025 · Cited by 264
Fragile X mental retardation protein and synaptic plasticity
Sidorov, M. S., Auerbach, B. D., & Bear, M. F. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-15 · Cited by 255
Targeting the endocannabinoid system in the treatment of fragile X syndrome
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., de la Torre, R., Dierssen, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3127 · Cited by 241
Metformin ameliorates core deficits in a mouse model of fragile X syndrome
Gantois, I., Khoutorsky, A., Popić, J., Aguilar‐Valles, A., Freemantle, E., Cao, R., Sharma, V. K., Pooters, T., Nagpal, A., Skalecka, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4335 · Cited by 240
Abnormal mTOR Activation in Autism
Winden, K. D., Ebrahimi‐Fakhari, D., & Şahin, M. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061747 · Cited by 232
Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function
Biever, A., Valjent, E., & Puighermanal, E. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00075 · Cited by 227
ERK/MAPK signalling in the developing brain: Perturbations and consequences
Iroegbu, J. D., Ijomone, O. K., Femi-Akinlosotu, O. M., & Ijomone, O. M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.009 · Cited by 212
Pausing on Polyribosomes: Make Way for Elongation in Translational Control
Richter, J. D., & Coller, J. (2015) · Cell · doi:10.1016/j.cell.2015.09.041 · Cited by 207
Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.064 · Cited by 201
Lai, K., & Ip, N. Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.012 · Cited by 182
Bariselli, S., Hörnberg, H., Prévost-Solié, C., Musardo, S., Hatstatt-Burklé, L., Scheiffele, P., & Bellone, C. (2018) · Nature Communications · doi:10.1038/s41467-018-05382-3 · Cited by 171
Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism
Huber, K. M., Klann, E., Costa-Mattioli, M., & Zukin, R. S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2656-15.2015 · Cited by 167
Self-citationEbrahimi‐Fakhari, D., & Şahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 177
Borrie, S. C., Brems, H., Legius, E., & Bagni, C. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035332 · Cited by 169
Kang, Y., Zhou, Y., Li, Y., Han, Y., Xu, J., Niu, W., Li, Z., Liu, S., Feng, H., Huang, W., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00913-6 · Cited by 168
Role of mTOR Complexes in Neurogenesis
Licausi, F., & Hartman, N. W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051544 · Cited by 172
Exercise training improves motor skill learning via selective activation of mTOR
Chen, K., Zheng, Y., Wei, J., Ouyang, H., Huang, X., Zhang, F., Lai, C. S. W., Ren, C., So, K., & Zhang, L. (2019) · Science Advances · doi:10.1126/sciadv.aaw1888 · Cited by 168
Deletion of PTEN produces autism-like behavioral deficits and alterations in synaptic proteins
Lugo, J. N., Smith, G. D., Arbuckle, E. P., White, J., Holley, A. J., Floruta, C. M., Ahmed, N., Gomez, M. C., & Okonkwo, O. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00027 · Cited by 162
Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1162-14.2014 · Cited by 155
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 157
Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes
Lee, J. H., Tecedor, L., Chen, Y. H., Mas, A., Sowada, M. J., Thompson, L. M., & Davidson, B. L. (2014) · Neuron · doi:10.1016/j.neuron.2014.12.019 · Cited by 151
Activation of autophagy rescues synaptic and cognitive deficits in fragile X mice
Yan, J., Porch, M. W., Court-Vazquez, B. L., Bennett, M. V. L., & Zukin, R. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808247115 · Cited by 146
mTOR signaling for biological control and cancer
Alayev, A., & Holz, M. K. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24351 · Cited by 143
Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology
Udagawa, T., Farny, N. G., Jakovcevski, M., Kaphzan, H., Alarcón, J. M., Anilkumar, S., Ivshina, M. P., Hurt, J. A., Nagaoka, K., Nalavadi, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3353 · Cited by 134
Self-citationA recollection of mTOR signaling in learning and memoryPreprint
Graber, T. E., McCamphill, P. K., & Sossin, W. S. (2013) · Learning & Memory · doi:10.1101/lm.027664.112 · Cited by 143
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091916 · Cited by 129
Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background
Ding, Q., Sethna, F., & Wang, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.046 · Cited by 131
How serotonin receptors regulate morphogenic signalling in neurons
Wirth, A., Holst, K., & Ponimaskin, E. G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.007 · Cited by 125
Of Men and Mice: Modeling the Fragile X Syndrome
Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133
Genetic and non-genetic animal models for autism spectrum disorders (ASD)
Ergaz, Z., Weinstein‐Fudim, L., & Ornoy, A. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.04.024 · Cited by 121
Gross, C., Chang, C.-W., Kelly, S. M., Bhattacharya, A., McBride, S. M. J., Danielson, S. W., Jiang, M. Q., Chan, C. B., Ye, K., Gibson, J. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.060 · Cited by 117
Self-citationIncreased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTor
Oguro-Ando, A., Rosensweig, C., Herman, E., Nishimura, Y., Werling, D., Bill, B. R., Berg, J. M., Gao, F., Coppola, G., Abrahams, B. S., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.124 · Cited by 117
ATP Synthase c-Subunit Leak Causes Aberrant Cellular Metabolism in Fragile X Syndrome
Licznerski, P., Park, H., Rolyan, H., Chen, R., Mnatsakanyan, N., Miranda, P., Graham, M. M., Wu, J., Cruz-Reyes, N., Mehta, N. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.008 · Cited by 119
mTOR, a Potential Target to Treat Autism Spectrum Disorder
Sato, A. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160413120638 · Cited by 117
Forrest, M. P., Waite, A. J., Martin‐Rendon, E., & Blake, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073169 · Cited by 112
Fragile X Syndrome: from molecular pathology to therapy
Maurin, T., Zongaro, S., & Bardoni, B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.006 · Cited by 113
Till, S. M., Asiminas, A., Jackson, A. D., Katsanevaki, D., Barnes, S. A., Osterweil, E. K., Bear, M. F., Chattarji, S., Wood, E. R., Wyllie, D. J. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv299 · Cited by 109
Banerjee, A., Ifrim, M. F., Valdez‐Sinon, A. N., Raj, N., & Bassell, G. J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.008 · Cited by 111
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
ERK/MAPK signaling and autism spectrum disorders
Vithayathil, J., Pucilowska, J., & Landreth, G. E. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.008 · Cited by 104
Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome
Jawaid, S., Kidd, G. J., Wang, J., Swetlik, C., Dutta, R., & Trapp, B. D. (2017) · Glia · doi:10.1002/glia.23284 · Cited by 93
mTOR Signaling Disruption and Its Association with the Development of Autism Spectrum Disorder
Thomas, S. D., Jha, N. K., Ojha, S. K., & Sadek, B. S. (2023) · Molecules · doi:10.3390/molecules28041889 · Cited by 106
Speranza, L., Labus, J., Volpicelli, F., Guseva, D., Lacivita, E., Leopoldo, M., Bellenchi, G. C., di Porzio, U., Bijata, M., Perrone‐Capano, C., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13962 · Cited by 93
Santini, E., Huynh, T. N., Longo, F., Koo, S. Y., Mojica, E. S., D’Andrea, L., Bagni, C., & Klann, E. (2017) · Science Signaling · doi:10.1126/scisignal.aan0665 · Cited by 92
Self-citationMetformin for treatment of fragile X syndrome and other neurological disorders
Gantois, I., Popic, J., Khoutorsky, A., & Sonenberg, N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-041238 · Cited by 87
Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice
Steinmetz, A. B., Stern, S. A., Kohtz, A. S., Descalzi, G., & Alberini, C. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2010-17.2017 · Cited by 90
Santos, A. R., Kanellopoulos, A. K., & Bagni, C. (2014) · Learning & Memory · doi:10.1101/lm.035956.114 · Cited by 91
Sawicka, K., Pyronneau, A., Chao, M., Bennett, M. V. L., & Zukin, R. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610812113 · Cited by 84
Wang, C.-C., Held, R. G., & Hall, B. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083941 · Cited by 90
Hippocampal dysfunction and cognitive impairment in Fragile-X Syndrome
Bostrom, C. A., Yau, S., Majaess, N. M., Vetrici, M. A., Gil‐Mohapel, J., & Christie, B. R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.033 · Cited by 87
Filippis, B. D., Nativio, P., Fabbri, A., Ricceri, L., Adriani, W., Lacivita, E., Leopoldo, M., Passarelli, F., Fuso, A., & Laviola, G. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.105 · Cited by 83
Fragile X mental retardation protein controls ion channel expression and activity
Ferron, L. (2016) · The Journal of Physiology · doi:10.1113/jp270675 · Cited by 80
Neurobiology of autism gene products: towards pathogenesis and drug targets
Kleijer, K. T. E., Schmeißer, M. J., Krueger‐Burg, D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3403-3 · Cited by 80
Gross, C., Raj, N., Molinaro, G., Allen, A. G., Whyte, A. J., Gibson, J. R., Huber, K. M., Gourley, S. L., & Bassell, G. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.065 · Cited by 71
Characterizing autism spectrum disorders by key biochemical pathways
Subramanian, M. P., Timmerman, C., Schwartz, J. L., Pham, D. L., & Meffert, M. K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00313 · Cited by 71
Han, K., Chen, H., Gennarino, V. A., Richman, R., Lu, H.-C., & Zoghbi, H. Y. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu595 · Cited by 72
Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 73
Control of Synaptic Plasticity and Memory via Suppression of Poly(A)-Binding Protein
Khoutorsky, A., Yanagiya, A., Gkogkas, C. G., Fabian, M. R., Prager‐Khoutorsky, M., Cao, R., Gamache, K., Bouthiette, F., Parsyan, A. E., Sorge, R. E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.025 · Cited by 72
Dougnon, G., & Matsui, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147550 · Cited by 76
Castrén, M. L., & Ċastrén, E. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.018 · Cited by 68
Talbot, Z. N., Sparks, F. T., Dvořák, D., Curran, B. M., Alarcón, J. M., & Fenton, A. A. (2018) · Neuron · doi:10.1016/j.neuron.2017.12.043 · Cited by 70
Antipsychotics Activate mTORC1-Dependent Translation to Enhance Neuronal Morphological Complexity
Bowling, H. L., Zhang, G., Bhattacharya, A., Pérez-Cuesta, L. M., Deinhardt, K., Hoeffer, C. A., Neubert, T. A., Gan, W., Klann, E., & Chao, M. V. (2014) · Science Signaling · doi:10.1126/scisignal.2004331 · Cited by 64
Self-citationGomis‐González, M., Busquets-García, A., Matute, C., Maldonado, R. J., Mato, S., & Ozaita, A. (2016) · Genes · doi:10.3390/genes7090056 · Cited by 64
Radwan, B., Dvorak, D., & Fenton, A. A. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.003 · Cited by 63
Lorsung, E., Ramanujam, K., & Cao, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.642745 · Cited by 67
Norepinephrine triggers metaplasticity of LTP by increasing translation of specific mRNAsPreprint
Maity, S., Rah, S. S., Sonenberg, N., Gkogkas, C. G., & Nguyen, P. (2015) · Learning & Memory · doi:10.1101/lm.039222.115 · Cited by 61
Qin, M., Huang, T., Kader, M., Krych, L., Xia, Z., Burlin, T., Zeidler, Z., Zhao, T., & Smith, C. B. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv034 · Cited by 62
Heise, C., Taha, E., Murru, L., Ponzoni, L., Cattaneo, A., Guarnieri, F. C., Montani, C., Mossa, A., Vezzoli, E., Ippolito, G., et al. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw075 · Cited by 62
Pirbhoy, P. S., Rais, M., Lovelace, J. W., Woodard, W., Razak, K. A., Binder, D. K., & Ethell, I. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15037 · Cited by 62
Kumari, D., Bhattacharya, A., Nadel, J., Moulton, K., Zeak, N. M., Glicksman, A., Dobkin, C., Brick, D. J., Schwartz, P. H., Smith, C. B., et al. (2014) · Human Mutation · doi:10.1002/humu.22699 · Cited by 61
Self-citationWhat we can learn from a genetic rodent model about autism
Möhrle, D., Fernández, M. C., Peñagarikano, O., Frick, A., Allman, B. L., & Schmid, S. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.015 · Cited by 60
mTOR in health and in sickness
Liko, D., & Hall, M. N. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1326-7 · Cited by 60
The p21-activated kinases in neural cytoskeletal remodeling and related neurological disorders
Zhang, K., Wang, Y., Fan, T., Zeng, C., & Sun, Z. S. (2020) · Protein & Cell · doi:10.1007/s13238-020-00812-9 · Cited by 60
Sethna, F., Feng, W., Ding, Q., Robison, A. J., Feng, Y., & Wang, H. (2017) · Nature Communications · doi:10.1038/ncomms14359 · Cited by 62
Magdalon, J., Sánchez-Sánchez, S. M., Griesi‐Oliveira, K., & Sertie, A. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030659 · Cited by 60
FMRP links optimal codons to mRNA stability in neurons
Shu, H., Donnard, E. R., Liu, B., Jung, S., Wang, R., & Richter, J. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009161117 · Cited by 60
Developmental onset distinguishes three types of spontaneous recognition memory in mice
Cruz-Sanchez, A., Dematagoda, S., Ahmed, R., Mohanathaas, S., Odenwald, N., & Arruda-Carvalho, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67619-w · Cited by 58
5-HT6 Receptor: A New Player Controlling the Development of Neural Circuits
Dayer, A. G., Jacobshagen, M., Chaumont‐Dubel, S., & Marin, P. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500326z · Cited by 63
Thurman, A. J., Potter, L. A., Kim, K., Tassone, F., Banasik, A., Potter, S. N., Bullard, L., Nguyen, V., McDuffie, A., Hagerman, R., et al. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09315-4 · Cited by 58
Liu, D., Nanclares, C., Simbriger, K., Fang, K., Lorsung, E., Le, N., Amorim, I. S., Chalkiadaki, K., Pathak, S. S., Li, J., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01499-6 · Cited by 56
Bowling, H. L., Bhattacharya, A., Zhang, G., Lebowitz, J. Z., Alam, D. H., Smith, P. T., Kirshenbaum, K., Neubert, T. A., Vogel, C., Chao, M. V., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.017 · Cited by 54
Self-citationShao, E., Chang, C.-W., Li, Z., Yu, X., Ho, K., Zhang, M., Wang, X., Simms, J., Lo, I., Speckart, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5527 · Cited by 54
Raj, N., McEachin, Z. T., Harousseau, W., Zhou, Y., Zhang, F., Merritt-Garza, M. E., Taliaferro, J. M., Kalinowska, M., Marro, S. G., Hales, C. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108991 · Cited by 54
Self-citationHyperactivity and lack of social discrimination in the adolescent Fmr1 knockout mouse
Sørensen, E. M., Bertelsen, F., Weikop, P., Skovborg, M. M., Banke, T. G., Drasbek, K. R., & Scheel‐Krüger, J. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000152 · Cited by 59
Bhattacharya, A., Mamcarz, M., Mullins, C., Choudhury, A., Boyle, R. G., Smith, D. G., Walker, D. W., & Klann, E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.369 · Cited by 51
Self-citationOrnoy, A., Weinstein‐Fudim, L., & Ergaz, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051074 · Cited by 57
Wang, A., Zou, X., Wu, J., Ma, Q., Yuan, N., Ding, F., Li, X., & Chen, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.590068 · Cited by 52
The autism-associated protein CHD8 is required for cerebellar development and motor function
Kawamura, A., Katayama, Y., Kakegawa, W., Ino, D., Nishiyama, M., Yuzaki, M., & Nakayama, K. I. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108932 · Cited by 53
Metadata
- Authors
- Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E.
- Affiliations
- New York University (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Klann, Eric
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 76
- Issue
- 2
- Pages
- 325-337
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC3479445
- OpenAlex
- W2147609603
- Cited by
- 316
- References
- 65
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 9 · 2023: 23 · 2022: 18 · 2021: 25 · 2020: 28 · 2019: 25 · 2018: 24 · 2017: 38 · 2016: 26 · 2015: 28 · 2014: 32 · 2013: 18 · 2012: 2
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R37NS034007, NS-047384, R01NS034007, R21NS078718, R29NS034007, NS-034007, R01NS047384)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fragile X syndrome, protein synthesis regulation, dendritic spine morphology, social interaction deficits, novel object recognition, behavioral inflexibility, intellectual disability, autism spectrum disorder
- MeSH terms
- Analysis of Variance, Animals, Behavior, Animal, Biophysics, Disease Models, Animal, Electric Stimulation, Exploratory Behavior, Female, Fragile X Syndrome, Gene Expression Regulation, Hippocampus, Interpersonal Relations, Male, Membrane Potentials, Methoxyhydroxyphenylglycol, Mice, Inbred C57BL, Mice, Transgenic, Motor Activity, Mutation, Neurons, Phenotype, Phosphorylation, Synapses, Patch-Clamp Techniques, Maze Learning, Excitatory Postsynaptic Potentials, Recognition, Psychology, Long-Term Synaptic Depression, Ribosomal Protein S6 Kinases, 70-kDa, Rotarod Performance Test, Extracellular Signal-Regulated MAP Kinases, Dendritic Spines, Mice, Fragile X Messenger Ribonucleoprotein 1, Fragile X Mental Retardation Protein, TOR Serine-Threonine Kinases, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
